Analysis of the Determinants of the Participation of Patients and Health Professionals of the University Hospital Center of Martinique in Clinical Research Protocols in Medical Oncology (StudyOrec)

NCT ID: NCT07206927

Last Updated: 2025-10-03

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

NOT_YET_RECRUITING

Total Enrollment

30 participants

Study Classification

OBSERVATIONAL

Study Start Date

2025-10-01

Study Completion Date

2027-01-01

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

For optimal patient care, it is imperative that healthcare professionals implement appropriate strategies. These strategies must take into account changes in healthcare practices associated with advances in medications and medical equipment. Clinical trials play a crucial role in validating the efficacy and safety of these advances, ensuring high-quality and constantly improving healthcare.

However the proportion of patients included in therapeutic trials is often considered too low.

Several ideas have been explored to explain the low participation rate in research projects. These are closely linked to research actors and tools, such as, for example:

* the research protocol and its eligibility criteria, which may be overly strict
* healthcare professionals with the barriers encountered in carrying out research programs (motivation, attitude and perceptions, human, logistical and technical constraints, lack of training)
* patients who are generally poorly acculturated to clinical research, the lack of information for patients in healthcare services, and patients' lack of trust in the healthcare system.
* ...

In Martinique, healthcare professionals face the same challenges in including patients in clinical trials.

Patient inclusion is necessary due to the region's demographic and medical characteristics. To improve patient inclusion in these trials, it is important to define the human and material barriers and levers that influence the participation of patients and healthcare professionals in clinical research protocols in the medical oncology departments of the Martinique University Hospital.

The investigators believe that increased patient awareness of the benefits of clinical research, equally increased incentives for healthcare professionals, and the establishment of adequate support structures would increase participation in clinical research protocols within the medical oncology departments of the Martinique University Hospital.

By conducting a mixed qualitative and quantitative study to gather the perspectives of patients and caregivers, the investigators aim to identify the human and material barriers that limit the participation of oncology patients in Martinique.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

As the French department with the oldest population, Martinique faces an over-incidence of certain diseases. For optimal patient care, it is imperative that healthcare professionals implement appropriate strategies. These strategies must take into account changes in healthcare practices associated with advances in medications and medical equipment. Clinical trials play a crucial role in validating the efficacy and safety of these advances, ensuring high-quality and constantly improving healthcare.

The goal of clinical research is to improve knowledge about a medication, a pathology, a procedure, or a treatment protocol.

Regardless of the specialty, clinical trials remain the only scientific means of demonstrating the quality and accuracy of information or the safety of medications or medical techniques.

Furthermore, offering a patient the opportunity to participate in a clinical trial is often a source of therapeutic alternatives or innovations.

It should be noted that the proportion of patients included in therapeutic trials is often considered too low.

Several ideas have been explored to explain the low participation rate in research projects. These are closely linked to the research stakeholders and tools. These include:

* The research protocol, particularly the eligibility criteria: In a survey conducted among sponsors on the factors influencing recruitment, the major barrier cited was identifying subjects who meet the eligibility criteria. These can be very strict, limiting the number of eligible patients.
* Healthcare professionals with the barriers encountered in carrying out research programs: They may be related to the investigator themselves (their motivation, attitude, and perceptions).

These parameters can have an impact on the patient's choice. In this study, the authors highlight the importance played by the investigator in recommending the trial to the patient. This is a decisive factor in their decision to participate in a clinical trial. This clearly demonstrates the trust patients place in their physician as the primary source of information regarding clinical trials.

There may also be limitations in terms of human, logistical, and technical constraints. Indeed, a lack of human resources is a recurring problem in research centers. Thus, after eligibility criteria, the second obstacle to patient participation in research projects is the lack of human resources at centers for patient recruitment (67% of respondents). Physicians are already overworked with care and may lack both logistical support and time to assist with recruitment.

A lack of training and specialized staff, as well as physicians' fear of negative reactions from their patients and the risk of disrupting the doctor-patient relationship of trust, are all factors also addressed in these articles.

* Patients with a lack of information: Few patients (15%) report being informed about ongoing clinical trials, while a greater number (75%) express a positive desire to participate in a clinical trial if they were aware of them. Patients may also not understand the importance of clinical trials or have concerns about the safety of clinical trials, the side effects of experimental treatments, or the possibility of receiving a placebo rather than the active treatment. There is also the trust that patients may place in the research world. Some patients may lack trust in the medical research system, which may discourage them from participating in clinical trials.
* Selection of trial sites: Clinical trials may not be available in all regions. Indeed, in their study by Allignet et al. show that the density of clinical trials in the French overseas departments is significantly lower than in mainland France, except in onco-dermatology.

Other authors have explored cross-cutting themes such as the association between scientific production and a specific research area or the inclusion of patients from ethnic and racial minorities in clinical trials.

In Martinique, healthcare professionals face the same challenges in including patients in clinical trials.

Patient inclusion is necessary due to the region's demographic and medical characteristics. To improve patient inclusion in these trials, it is important to define the human and material barriers and levers that influence the participation of patients and healthcare professionals in clinical research protocols in the medical oncology departments of the Martinique University Hospital.

Research Hypotheses:

The investigators believe that increased patient awareness of the benefits of clinical research, equally increased incentives for healthcare professionals, and the establishment of adequate support structures would increase participation in clinical research protocols within the medical oncology departments of the Martinique University Hospital.

By conducting a mixed qualitative and quantitative study to gather the perspectives of patients and caregivers, the investigators aim to identify the human and material barriers that limit the participation of oncology patients in Martinique.

The qualitative method requires the support of professionals in the humanities and social sciences (HSS) who can provide methodological support and experience in patient interviews.

This is why the research team chose to be accompanied by a sociologist and an anthropologist who already have experience in the health field in Martinique, particularly with patients suffering from prostate cancer.

Secondly, the results of this study will be used to establish appropriate organizational structures for the participation of patients in Martinique in oncology clinical research protocols.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Oncologic Diseases Cancer Oncology

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

PROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Qualitative Study : Patients interviews

For the qualitative part, 30 patients will be included in the study. A semi-structured interview, lasting 20 to 30 minutes, will be conducted by the sociologist and anthropologist. They will use questionnaires (semi-structured interview grids), administered to patients face-to-face or by telephone. Patients will be interviewed only once.

The interview grid includes the following sections: personal characteristics such as age, family and professional situation, municipality of residence, and knowledge of clinical research.

Qualitative Study: Semi-structured interview for patients

Intervention Type OTHER

A semi-structured interview, lasting 20 to 30 minutes, will be conducted by the sociologist and anthropologist. They will use questionnaires (semi-structured interview grids), administered to patients face-to-face or by telephone. Patients will be interviewed only once. The interview grid includes the following sections: personal characteristics such as age, family and professional situation, municipality of residence, and knowledge of clinical research.

Quantitative Study : Healthcare professionals questionnaires

For the qualitative part, 30 healthcare professionnals will be included in the study.

Questionnaires will be administered by email, in a single session, to healthcare professionals who have agreed to participate in the study.

Quantitative Study : Healthcare professionals questionnaires

Intervention Type OTHER

Questionnaires will be administered by email, in a single session, to healthcare professionals who have agreed to participate in the study.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Qualitative Study: Semi-structured interview for patients

A semi-structured interview, lasting 20 to 30 minutes, will be conducted by the sociologist and anthropologist. They will use questionnaires (semi-structured interview grids), administered to patients face-to-face or by telephone. Patients will be interviewed only once. The interview grid includes the following sections: personal characteristics such as age, family and professional situation, municipality of residence, and knowledge of clinical research.

Intervention Type OTHER

Quantitative Study : Healthcare professionals questionnaires

Questionnaires will be administered by email, in a single session, to healthcare professionals who have agreed to participate in the study.

Intervention Type OTHER

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Male or female,
* Age ≥ 18 years,
* Patient being treated for cancer at the University Hospital Center of Martinique,
* Patient who can read and/or understand French,
* Patient who has consented to the use of their medical data for this research.


\- Any qualified healthcare professional working in the medical oncology departments of the University Hospital Center of Martinique, such as oncologists, radiation therapists, urologists, nurses, etc.

Exclusion Criteria

* Patient with known cognitive impairments that prevent them from completing the questionnaire,
* Subjects under legal protection (guardianship/curatorship),
* Subjects at an advanced stage of the disease (asthenia),
* Written or oral objection from the patient to the use of data for research purposes.


* Students in training regardless of their field,
* Replacement healthcare professionals for a period of less than 12 months.
Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

KaFE Association (Karaib Formation Etudes)

UNKNOWN

Sponsor Role collaborator

University Hospital Center of Martinique

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Mickaëlle ROSE

Role: PRINCIPAL_INVESTIGATOR

University Hospital Center of Martinique

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

University Hospital Center of Martinique

Fort-de-France, , Martinique

Site Status

Countries

Review the countries where the study has at least one active or historical site.

Martinique

Central Contacts

Reach out to these primary contacts for questions about participation or study logistics.

Mickaëlle ROSE

Role: CONTACT

05 96 59 26 23 ext. +596

Facility Contacts

Find local site contact details for specific facilities participating in the trial.

Mickaëlle ROSE

Role: primary

05 96 59 26 23 ext. +596

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

2025-A01419-40

Identifier Type: OTHER

Identifier Source: secondary_id

24_RIPH3-04

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

CAncer, NUtrition and Taste 2
NCT05027490 COMPLETED NA